Business

With increasing access and utilization of healthcare, resources become more restricted, and prioritization in healthcare becomes unavoidable. Health economics and outcomes research (HEOR) is a discipline that is used to complement traditional clinical development information (ie, efficacy, safety, quality) to guide decision makers regarding patient access to specific drugs and services. HEOR has advanced considerably in methodology and in quantity over the past several decades.

Health Economics and Outcomes Research Data Key in Coverage Decisions of New Medications

Myelodysplastic syndrome (MDS) encompasses a heterogeneous group of clonal disorders of hematopoiesis and is characterized by dysplastic morphology of marrow and blood cells, ineffective hematopoiesis, and peripheral blood cytopenias.1,2 Most patients with MDS experience progressive worsening of blood cytopenias, with an increasing need for transfusion.2 These patients also have an increasing number of potentially fatal infections and hemorrhagic complications.2 The more advanced and severe the MDS is, the greater the risk that the disease will progress to a

Reconsidering the Management of Younger Patients with Myelodysplastic Syndrome

Bipolar disorder is a chronic, recurring disorder associated with frequent episodes of mania and depression.

The Potential Value of Benefit Design and Medication Selection for a Total-Cost-of-Care Strategy in Bipolar Disease

The eighteenth-century essayist and satirist Jonathan Swift made the observation that “vision is the art of seeing things invisible.” So, too, is “the art of seeing things invisible” a key for the ongoing sustainability of health information exchange (HIE). HIEs have long been theorized to provide a number of tangible benefits.

Significant Potential for Health Information Exchange in Enhancing Quality of Care and Reducing Hospital Admissions in the United States

The growing impact of specialty injectables and biologic agents on the budgets of health plan sponsors is undeniable.

Managing Medical Benefit Drugs Under Specialty Pharmacy: The Next Critical Challenge for Managed Care
According to the American Cancer Society, more than 1.6 million new cancer cases will be diagnosed in 2012, and more than 577,000 Americans are expected to die of cancer this year.

Pompe disease is a rare condition, with a global incidence rate estimated to be between 1 in 40,000 (0.0025%) and 1 in 300,000 (0.0003%) live births.1 According to a study published in 1998, the annual incidence of Pompe disease in New York City was estimated to be approximately 1 in 40,000 births, and approximately 90 babies are assumed born with Pompe disease in the United States annually.2 A similar incidence rate was found in the Dutch population (1 in 40,000 births), a relatively lower rate was found among the Chinese (1 in 50,000 births; 0.0020%), and a higher ra

Beyond “Patient Amusement”: New Treatments and Genetic Disease

Atrial fibrillation (AF) is a significant health and cost concern for the Medicare population (age ≥65 years), because of its association with an increased risk for stroke and all-cause mortality.1 The risk for stroke in patients with AF is almost 5-fold higher than in patients without AF.2 One of every 6 strokes in the United States is associated with AF,3 and strokes in patients with AF are more severe and disabling than in patients without AF.4 The prevalence of AF in the Medicare population increased from 3.2% in 1992 to 6.0% in 2002.5

Warfarin Utilization in Medicare Patients with Nonvalvular Atrial Fibrillation: Sentinel Data from an Administrative Claims Database

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disorder and the most common form of inflammatory arthritis.1 RA affects 1% of the population, most often adults aged 40 to 70 years.2 Recent epidemiologic data indicate that the incidence of RA in women has risen in the past 10 years.3 Because RA affects many individuals who are of working age and remains a major cause of disability, the economic burden of RA adds a significant cost not only to patients and their families, but also to society as a whole.1,4 In addition, reduced quality of

Biologic Therapies for Rheumatoid Arthritis: It's All about Value

Pulmonary arterial hypertension (PAH) is a progressive disorder characterized by abnormally high blood pressure (ie, hypertension) in the pulmonary artery, with 1000 new cases being diagnosed annually in the United States, based on a 2009 report.1 Because of the complex nature of PAH and its treatments, healthcare providers must closely follow patients with PAH; depending on the stage of the illness, patients should generally be seen by a physician every 3 to 6 months according to the 2009 American College of Cardiology Foundation Task Force on Expert Consensus Documents and the

The Challenges of Pulmonary Arterial Hypertension Management: Potential Benefits of Removing Monthly Testing
Page 7 of 12
Results 61 - 70 of 111
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME